Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Pharma's Bad Attitude: Are CEOs Giving Industry A Bad Rep?

Executive Summary

Big pharma has been big news recently, with politicians and the general public wading into industry debates on drug pricing, profit-making and trial transparency under the gleeful eye of the international press. Unsurprisingly, pharma has come out on the losing side of these debates, its scientific accomplishments forced into the shadows by the actions of executives such as Martin Shkreli, who have ensured that the spotlight is firmly on the people behind the businesses rather than the products they manufacture.

You may also be interested in...

Another Black Eye For Valeant, But Salix Is The Culprit

Long before Valeant Pharmaceuticals International Inc. acquired North Carolina-based Salix Pharmaceuticals Ltd. in 2015, the latter firm was engaging in illegal kickback activities, for which its parent company is now left holding the bag in paying out $54m to settle the charges – another black eye for the Canadian firm's reputation.

Patient Groups Rank ViiV Top Of Pharma Reputation League Table, Again

The latest PatientView report on the corporate reputation of pharma from the perspective of patient groups has been published. In a survey of pharma's corporate reputation, ViiV Healthcare retained the overall top spot, with AbbVie a close second. Of the 48 companies that patient groups commented on, the bottom ranked companies were Valeant and Hospira.

Pfizer's Martine J. George joins GarmaMabs

GarmaMabs Pharma has appointed Martine J. George an independent board member.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts